<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03217851</url>
  </required_header>
  <id_info>
    <org_study_id>BAKMAL 1701</org_study_id>
    <nct_id>NCT03217851</nct_id>
  </id_info>
  <brief_title>Prevalence Survey of Antimalarial Drug Resistance Markers</brief_title>
  <official_title>Prevalence Survey of Plasmodium Falciparum Antimalarial Drug Resistance Markers in Greater Mekong Subregion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Worldwide Antimalarial Resistance Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mahidol Oxford Tropical Medicine Research Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Myanmar Oxford Clinical Research Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shoklo Malaria Research Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oxford University Clinical Research Unit, Vietnam</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cambodia Oxford Medical Research Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study is cross-sectional and observational with one-time dried-blood spot sample collection
      from persons with laboratory-confirmed uncomplicated Plasmodium falciparum malaria (mixed or
      monoinfection). Samples will be analysed for the presence of molecular markers of resistance
      to ACT partner drugs (gene amplifications and/or other mutations in pfmdr1, gene
      amplifications of pfpm2, and additional mutations which may be identified during the course
      of the trial) in the first instance. Testing to detect additional markers of antimalarial
      drug resistance will also be performed where feasible. Prevalence of mutations will be
      summarized and mapped to provide intelligence on antimalarial drug resistance in the region
      of interest.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Malaria Malaria is caused by a mosquito-borne, protozoan parasite belonging to the genus
      Plasmodium. Of the five species of Plasmodium that infect humans, Plasmodium falciparum is
      the most deadly and is responsible for the majority of malaria disease and death. Every year,
      falciparum malaria causes disease in hundreds of millions of people living in the tropics and
      subtropics, killing a million or more according to some estimates. The vast majority of these
      deaths occur in sub-Saharan Africa, mostly among young children and infants. When treated
      with effective antimalarial drugs, malaria can be cured completely.

      Antimalarial drug resistance The emergence in Southeast Asia and the subsequent global spread
      of drug resistant malaria was a major factor contributing to the failure of the first global
      malaria eradication campaign in the mid-20th century (1). The widespread implementation of
      highly effective artemisinin-based combination therapy (ACT) for malaria has contributed to
      significant gains in global control and elimination efforts and has brought malaria
      eradication back on the agenda, 40 years after the first global malaria eradication campaign
      was abandoned (2). However the gains seen in the past decade are now at risk as parasite
      resistance to artemisinin compounds has been confirmed in Southeast Asia and threatens Africa
      once again (3-8). In the absence of effective vaccines, it is critical to prolong the usable
      life of antimalarial drugs by judicious implementation of treatment strategies.

      Primary Objective To measure prevalence of established and candidate molecular markers of
      drug resistant malaria in Greater Mekong Subregion

      Secondary Objective To map the geographical and temporal changes in prevalence of molecular
      markers of antimalarial drug resistance in Greater Mekong Subregion
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 18, 2017</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence and geospatial trends of molecular markers, information to assist definition of treatment policies</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visualization and dissemination of molecular marker prevalence data to inform public health officials, researchers, policymakers and key stakeholders</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2940</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Patients Presenting P. falciparum Malaria</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood Collection</intervention_name>
    <description>blood smear and/or rapid diagnostic</description>
    <arm_group_label>Patients Presenting P. falciparum Malaria</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Dried Blood Spot</intervention_name>
    <description>Dried Blood Spot on filter paper</description>
    <arm_group_label>Patients Presenting P. falciparum Malaria</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Collect blood for malaria diagnostic testing (blood smear and/or rapid diagnostic test) and
      dried blood spot on filter paper
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients age 6 months - 75 years presenting at study site with confirmed P. falciparum
        infection
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients (6 months - 75 years) with confirmed uncomplicated P. falciparum infection

          -  Written informed consent obtained (by parents/guardian in case of children less than
             18 years old)

        Exclusion Criteria:

        Patients presenting signs of severe malaria* will be excluded from the survey to prevent
        any delay in the management of the patient.

        *Guideline for the treatment of Malaria-3rd edition, WHO (27) Severe falciparum malaria is
        defined as one or more of the following, occurring in the absence of an identified
        alternative cause and in the presence of P.falciparum asexual parasitaemia.

          -  Impaired consciousness: A Glasgow comma score &lt; 11 in adults or Blantyre coma score &lt;
             3 in children

          -  Prostration: Generalized weakness so that the person is unable to sit, stand or walk
             without assistance.

          -  Multiple convulsions: More than two episodes within 24 h

          -  Acidosis: A base deficit of &gt; 8 mEq/L or, if not available a plasma bicarbonate level
             of &lt; 15 mmol/L or venous plasma lactate ≥ 5 mmol/L. Severe acidosis manifests
             clinically as respiratory distress (rapid, deep, laboured breathing).

          -  Hypoglycaemia: Blood or plasma glucose &lt; 2.2 mmol/L (&lt;40 mg/dL)

          -  Severe malarial anaemia: Haemoglobin concentration ≤ 5 g/dL or a haematocrit of ≤ 15%
             in children &lt; 12 years of age (&lt; 7 g/dL and &lt; 20%, respectively, in adults) with a
             parasite count &gt; 10,000/µL

          -  Renal impairment: Plasma or serum creatinine &gt; 265 µmol/L (3 mg/dL) or blood urea &gt; 20
             mmol/L

          -  Jaundice: Plasma or serum bilirubin &gt; 50 µmol/L (3 mg/dL) with a parasite count &gt;
             100,000/ µL

          -  Pulmonary oedema: Radiologically confirmed or oxygen saturation &lt; 92% on room air with
             a respiratory rate &gt; 30/min, often with chest indrawing and crepitations on
             auscultation

          -  Significant bleeding: Including recurrent or prolonged bleeding from the nose, gums or
             venepuncture site; haematemesis or melaena

          -  Shock: Compensated shock is defined as capillary refill ≥ 3 s or temperature gradient
             on leg (mid to proximal limb), but no hypotension. Decompensated shock is defined as
             systolic blood pressure &lt; 70 mm Hg in children or &lt; 80 mm Hg in adults, with evidence
             of impaired perfusion (cool peripheries or prolonged capillary refill)

          -  Hyperparasitaemia: P.falciparum parasitaemia &gt; 10%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francois Nosten, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Shoklo Malaria Research Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank Smithuis, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Myanmar Oxford Clinical Research Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mayfong Mayxay, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nguyen Thanh Thuy Nhien, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oxford University Clinical Research Unit, Vietnam</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arjen M. Dondorp, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol Oxford Clinical Research Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mallika Imwong, PhD</last_name>
    <phone>+66 (0) 23 54 91 00</phone>
    <phone_ext>3078</phone_ext>
    <email>mallika.imw@mahidol.ac.th</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mehul Dhorda, PhD</last_name>
    <phone>+66 (0) 23 54 91 28</phone>
    <email>mehul.dhorda@wwarn.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shoklo Malaria Research Unit</name>
      <address>
        <city>Mae Sot</city>
        <state>Tak</state>
        <zip>63110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suttipat Srisutham</last_name>
      <email>Suttipat@tropmedres.ac</email>
    </contact>
    <contact_backup>
      <last_name>Francois Nosten, MD</last_name>
      <phone>+(66) 55545021</phone>
      <email>francois@tropmedres.ac</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2017</study_first_submitted>
  <study_first_submitted_qc>July 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plasmodium falciparum</keyword>
  <keyword>Prevalence Survey</keyword>
  <keyword>Antimalarial Drug</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antimalarials</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

